Involvement of sphingomyelinase in insulin-induced phosphatidylinositol 3-kinase activation.
Huang
C
C
The Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA.
Ma
W Y
WY
Ding
M
M
Li
J
J
Shi
X
X
Castranova
V
V
Vallyathan
V
V
Bode
A M
AM
Dong
Z
Z
D000818:Animals; D002478:Cells, Cultured; D004347:Drug Interactions; D004789:Enzyme Activation / Q000187:drug effects; D004790:Enzyme Induction / Q000187:drug effects; D004817:Epidermis / Q000187:drug effects* / Q000201:enzymology; D001556:Hexachlorocyclohexane / Q000031:analogs & derivatives / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology*; D051379:Mice; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism / Q000502:physiology*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D007328:Insulin; C064769:N-acetylsphingosine; D010975:Platelet Aggregation Inhibitors; D001556:Hexachlorocyclohexane; C043572:1,3,4,5,6-pentachlorocyclohexene-1-oxide; D019869:Phosphatidylinositol 3-Kinases; D013108:Sphingomyelin Phosphodiesterase; D013110:Sphingosine